2023-03-16 09:36:02 ET
- Clearmind Medicine ( NASDAQ: CMND ) stock rose ~10% on Thursday after the company said it filed an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) seeking approval to start a phase 1/2a trial of CMND-100 in patients with alcohol use disorder (AUD).
- The company plans to begin the study in Q2 2023, subject to FDA approval of the IND.
- Clearmind noted that the active ingredient in CMND-100 is MEAI (5-methoxy-2-aminoindane), a novel psychoactive molecule which has been reported to decrease the desire to consume alcoholic beverages while exerting a euphoric alcohol-like experience.
- "From studies with MEAI, we believe it has potential to break the vicious drinking cycle at the point of the decision to drink more alcohol, by potentially innervating neural pathways that lead to sensible behavior," said Clearmind's CEO Adi Zuloff-Shani.
For further details see:
Clearmind stock rises on FDA filing to start trial of alcohol use disorder therapy